<DOC>
	<DOCNO>NCT02035722</DOCNO>
	<brief_summary>Intravitreal injection Ranibizumab ( Lucentis , Genentech ) clinically indicated patient wet age-related macular degeneration ( AMD ) An disadvantage technique anxiety discomfort patient often experience due idea `` get needle eye '' . In addition , recent case study indicate importance patient education achieve positive outcome intravitreal injection anti-vascular endothelial growth factor ( VEGF ) agent . The purpose study determine whether visual education AMD intravitreal injection reduce patient ' anxiety prior treatment , lessen impact socioeconomical status understand treatment prognosis .</brief_summary>
	<brief_title>Intravitreal Injections-related Anxiety</brief_title>
	<detailed_description>The use intravitreal injection Ranibizumab ( Lucentis , Genentech ) become increase common management age-related macular degeneration ( AMD ) . It therefore important acknowledge address patient ' anxiety due anticipate discomfort idea `` get needle eye '' . In addition , visual provision information diagnosis concern long-term treatment expectation may enhance informed consent process . The use visual aid may also accommodate patient different educational background present new complex treatment information . The purpose study determine whether visual education AMD intravitreal injection reduce patient ' anxiety prior treatment , lessen impact socioeconomical status understand treatment prognosis . Although tool develop context injection-requiring retinal disease , application care disease require long-term treatment .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>18 year old AMD patient require intravitreal injection Unable read comprehend English Any contraindication intravitreal injection , IOP elevation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>